(4-bromophenyl)(methylsulfonyl)amino acetic acid | 425423-24-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-bromophenyl)(methylsulfonyl)amino acetic acid
• 英文别名: 2-(4-bromo-N-methylsulfonylanilino)acetic acid
• CAS: 425423-24-1
• 化学式: C₉H₁₀BrNO₄S
• mdl: MFCD02218528
• 分子量: 308.153
• InChiKey: HPPVMNBRJXQJIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4-bromophenyl)(methylsulfonyl)amino acetic acid 、 4-氰基苯硼酸 在 fibrecat FC₁₀₀₁ sodium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 0.25h， 以5%的产率得到(4'-cyano-1,1'-biphenyl-4-yl)(methylsulfonyl)amino-acetic acid
  参考文献：
  名称：

  [EN] INHIBITORS OF MATRIX METALLOPROTEINASE
  [FR] INHIBITEURS DE LA METALLOPROTEINASE DE LA MATRICE

  摘要：

  式（I）的化合物，其中R1代表可选择取代的C4-12烷基，可选择取代的C2-6烷基芳基，或可选择取代的5-或6-成员芳基或杂芳基；Z代表键，CH2，O，S，SO，SO2，NR4，OCR4R5，CR4R5O或Z，R1和Q共同形成可选择取代的融合三环基团；Q代表可选择取代的5-或6-成员芳基或杂芳基环；X代表COR3或N（OR8）COR9；R2代表SO2R10或SO2NR10R11；R3代表OR6，NR6R7或NR6OH；R4和R5各自独立地代表H，C1-6烷基或C1-4烷基芳基；R6和R7各自独立地代表H，C1-6烷基，或C1-6烷基上取代一个或多个杂芳基团，或R6和R7与它们连接的氮原子共同形成可能包括1个或更多来自O、S和N的进一步杂原子的5-或6-成员环；R8和R9各自独立地代表H或C1-6烷基；R10和R11各自独立地代表H或C1-6烷基；以及其生理功能衍生物，除了N-（乙氧羰基）-N-[4-(1H-四唑-1-基)苯基]甘氨酸，描述了其制备方法，含有它们的药物配方和它们作为基质金属蛋白酶酶（MMPs）抑制剂的用途。

  公开号：

  WO2004113279A1
• 作为产物：
  描述：

  tert-butyl [(4-bromophenyl)(methylsulfonyl)amino]acetate 在 silica gel 、 methanol-dichloromethane 作用下， 以 甲苯 为溶剂， 反应 4.0h， 以gave the title compound as a white solid (0.81 g, 95%)的产率得到(4-bromophenyl)(methylsulfonyl)amino acetic acid
  参考文献：
  名称：

  Inhibitors of matrix metalloproteinase

  摘要：

  化合物的式子(I)：其中，R1代表可选取代的C4-12烷基，可选取代的C2-6烷基芳基，或可选取代的5或6元杂环芳基或杂芳基；Z代表键，CH2，O，S，SO，SO2，NR4，OCR4R5，CR4R5O或Z，R1和Q共同形成可选取代的融合三环基团；Q代表可选取代的5或6元杂环芳基或杂芳基环；X代表COR3或N（OR8）COR9；R2代表SO2R10或SO2NR10R11；R3代表OR6，NR6R7或NR6OH；R4和R5各自独立地代表H，C1-6烷基或C1-4烷基芳基；R6和R7各自独立地代表H，C1-6烷基，或C1-6烷基取代一个或多个杂芳基基团，或R6和R7与它们连接的氮原子一起形成一个可选取代的5或6元杂环，该杂环可选择包括1个或多个进一步选择的杂原子，包括O，S和N；R8和R9各自独立地代表H或C1-6烷基；R10和R11各自独立地代表H或C1-6烷基；以及其生理学功能衍生物，除N-(乙氧羰基)-N-[4-(1H-四唑-1-基)苯基]甘氨酸外，还描述了它们的制备过程，含有它们的制药配方以及它们作为基质金属蛋白酶酶（MMPs）抑制剂的用途。

  公开号：

  US07375248B2

文献信息

• [EN] MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEINASES MATRICIELLES
  申请人：GLAXO GROUP LTD

  公开号：WO2005026120A1

  公开（公告）日：2005-03-24

  Compounds of Formula (I): Wherein: A represents bond, C1-6alkyl or CH=CH-C1-4alkyl; B represents bond, O, S, SO, SO2, CO, CR7R8, CO2R14, CONR14R15, N(COR14)(COR15), N(SO2R14)(COR15) or NR14R15; D represents bond, or C1-6alkyl; E represents substituted aryl or substituted or unsubstituted heteroaryl; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents O, S, SO, SO2, CO, CNR5, CNOR5, CNNR5R6, NR11 or CR7R8; Y represents CR5OR11, CR5SR11, NOR5, CR5NR6R11, SO, SO2, CO, CNR5, CNOR5 or CS; R1 and R1' each independently represents H, C1-6alkyl or C1-4alkylaryl; R2 represents CO2R12, CH2OR12 or CONR12R13, CONR12OR13, NR12COR13, SR12, PO(OH)2, PONHR12 or SONHR12; R3 represents H, C1-6alkyl or C1-4alkylaryl; R4 represents optionally substituted aryl or heteroaryl; Z represents a bond, CH2, O, S, SO, SO2, NR5, OCR5R6, CR9R10O or Z, R4 and Q together form an optionally substituted fused tricyclic group; R5 and R6 each independently represent H, C1-6 alkyl or C1-4 alkylaryl; R7 and R8 each independently represent H, halo, C1-6 alkyl or C1-4 alkylaryl; R9 and R10 each independently represents H, C1-6 alkyl optionally substituted by halo, cyano, OR11 or NR6R11 , C1-4 alkylaryl optionally substituted by halo, cyano, OR11 or NR6R11, OR11 or, together with the N to which they are attached, R9 and R10 form a heterocyclic group: R11 represents H, C1-6 alkyl, C1-4 alkylaryl or COR5; R12 and R13 each independently represent H, C1-3 alkyl, C1-3 alkylaryl or C1-3 alkylheteroaryl or, together with the functionality to which they are attached, R12 and R13 form a heterocyclic group: R14 and R15 each independently represent H, C1-6 alkyl, C1-4 alkylaryl or C1-4 alkylheteroaryl or together with the functionality to which they are attached R14 and R15 form a heterocyclic or fused heterocyclic group: and physiologically functional derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs) are described.

  式(I)的化合物：其中：A代表键，C1-6烷基或CH=CH-C1-4烷基；B代表键，O，S，SO，SO2，CO，CR7R8，CO2R14，CONR14R15，N(COR14)(COR15)，N(SO2R14)(COR15)或NR14R15；D代表键，或C1-6烷基；E代表取代芳基或取代或未取代的杂环芳基；Q代表可选择取代的5-或6-成员芳基或杂环芳基环；X代表O，S，SO，SO2，CO，CNR5，CNOR5，CNNR5R6，NR11或CR7R8；Y代表CR5OR11，CR5SR11，NOR5，CR5NR6R11，SO，SO2，CO，CNR5，CNOR5或CS；R1和R1'各自独立地代表H，C1-6烷基或C1-4烷基芳基；R2代表CO2R12，CH2OR12或CONR12R13，CONR12OR13，NR12COR13，SR12，PO(OH)2，PONHR12或SONHR12；R3代表H，C1-6烷基或C1-4烷基芳基；R4代表可选择取代的芳基或杂环芳基；Z代表键，CH2，O，S，SO，SO2，NR5，OCR5R6，CR9R10O或Z，R4和Q共同形成可选择取代的融合三环基团；R5和R6各自独立地代表H，C1-6烷基或C1-4烷基芳基；R7和R8各自独立地代表H，卤素，C1-6烷基或C1-4烷基芳基；R9和R10各自独立地代表H，可选择由卤素，氰基，OR11或NR6R11取代的C1-6烷基，可选择由卤素，氰基，OR11或NR6R11取代的C1-4烷基芳基，OR11或，与它们连接的N一起，R9和R10形成杂环基团：R11代表H，C1-6烷基，C1-4烷基芳基或COR5；R12和R13各自独立地代表H，C1-3烷基，C1-3烷基芳基或C1-3烷基杂环芳基或，与它们连接的官能团一起，R12和R13形成杂环基团：R14和R15各自独立地代表H，C1-6烷基，C1-4烷基芳基或C1-4烷基杂环芳基或与它们连接的官能团一起，R14和R15形成杂环或融合杂环基团：以及其生理功能衍生物，其制备方法，含有它们的制药配方以及它们作为基质金属蛋白酶酶（MMPs）抑制剂的用途。
• Matrix metalloproteinase inhibitors
  申请人：Gaines Simon

  公开号：US20060293353A1

  公开（公告）日：2006-12-28

  Compounds of Formula (I): wherein: A represents bond, C 1-6 alkyl or CH═CH—C 1-4 alkyl; B represents bond, 0, S, SO, SO 2 , CO, CR 7 R 8 , CO 2 R 14 , CONR 14 R 15 , N(COR 14 )(COR 15 ), N(SO 2 R 14 )(COR 15 ) or NR 14 R 15 ; D represents bond, or C 1-6 alkyl; E represents substituted aryl or substituted or unsubstituted heteroaryl; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents O, S, SO, SO 2 , CO, CNR 5 , CNOR 5 , CNNR 5 R 6 , NR 11 or CR 7 R 8 ; Y represents CR 5 OR 11 , CR 5 SR 11 , NOR 5 , CR 5 NR 6 R 11 , SO, SO 2 , CO, CNR 5 , CNOR 5 or CS; R 1 and R 1′ each independently represents H, C 1-6 alkyl or C 1-4 alkylaryl; R 2 represents CO 2 R 12 , CH 2 OR 12 or CONR 12 R 13 , CONR 12 OR 13 , NR 12 COR 13 , SR 12 , PO(OH) 2 , PONHR 12 or SONHR 12 ; R 3 represents H, C 1-6 alkyl or C 1-4 alkylaryl; R 4 represents optionally substituted aryl or heteroaryl; Z represents a bond, CH 2 , O, S, SO, SO 2 , NR 5 , OCR 5 R 6 , CR 9 R 10 O or Z, R 4 and Q together form an optionally substituted fused tricyclic group; R 5 and R 6 each independently represent H, C 1-6 alkyl or C 1-4 alkylaryl; R 7 and R 8 each independently represent H, halo, C 1-6 alkyl or C 1-4 alkylaryl; R 9 and R 10 each independently represents H, C 1-6 alkyl optionally substituted by halo, cyano, OR 11 or NR 6 R 11 , C 1-4 alkylaryl optionally substituted by halo, cyano, OR11 or NR 6 R 11 , OR 11 or, together with the N to which they are attached, R 9 and R 10 form a heterocyclic group: R 11 represents H, C 1-6 alkyl, C 1-4 alkylaryl or COR 5 ; R 12 and R 13 each independently represent H, C 1-3 alkyl, C 1-3 alkylaryl or C 1-3 alkylheteroaryl or, together with the functionality to which they are attached, R 12 and R 13 form a heterocyclic group: R 14 and R 15 each independently represent H, C 1-6 alkyl, C 1-4 alkylaryl or C 1-4 alkylheteroaryl or together with the functionality to which they are attached R 14 and R 15 form a heterocyclic or fused heterocyclic group; and physiologically functional derivatives thereof, corresponding processes for preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs).

  化合物的化学式（I）：其中：A代表键，C1-6烷基或CH═CH—C1-4烷基；B代表键，0，S，SO，SO2，CO，CR7R8，CO2R14，CONR14R15，N（COR14）（COR15），N（SO2R14）（COR15）或NR14R15；D代表键或C1-6烷基；E代表取代芳基或取代或未取代的杂环芳基；Q代表可选取代的5-或6-成员芳基或杂环芳基环；X代表O，S，SO，SO2，CO，CNR5，CNOR5，CNNR5R6，NR11或CR7R8；Y代表CR5OR11，CR5SR11，NOR5，CR5NR6R11，SO，SO2，CO，CNR5，CNOR5或CS；R1和R1′各自独立地表示H，C1-6烷基或C1-4烷基芳基；R2表示CO2R12，CH2OR12或CONR12R13，CONR12OR13，NR12COR13，SR12，PO（OH）2，PONHR12或SONHR12；R3表示H，C1-6烷基或C1-4烷基芳基；R4表示可选取代的芳基或杂环芳基；Z表示键，CH2，O，S，SO，SO2，NR5，OCR5R6，CR9R10O或Z，R4和Q一起形成可选取代的融合三环基团；R5和R6各自独立地表示H，C1-6烷基或C1-4烷基芳基；R7和R8各自独立地表示H，卤素，C1-6烷基或C1-4烷基芳基；R9和R10各自独立地表示H，C1-6烷基，可选取代的卤素，氰基，OR11或NR6R11，C1-4烷基芳基，可选取代的卤素，氰基，OR11或NR6R11，OR11或与它们所连接的N一起，R9和R10形成杂环基团；R11表示H，C1-6烷基，C1-4烷基芳基或COR5；R12和R13各自独立地表示H，C1-3烷基，C1-3烷基芳基或C1-3烷基杂环芳基或与它们所连接的官能团一起，R12和R13形成杂环基团；R14和R15各自独立地表示H，C1-6烷基，C1-4烷基芳基或C1-4烷基杂环芳基或与它们所连接的官能团一起，R14和R15形成杂环或融合杂环基团；以及其生理活性衍生物，对应的制备过程，含有它们的制药配方以及它们作为基质金属蛋白酶酶（MMPs）抑制剂的用途。
• MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Gaines Simon

  公开号：US20100029699A1

  公开（公告）日：2010-02-04

  The present invention relates to compounds of Formula (I): pharmaceutically acceptable salts thereof, corresponding preparation processes, pharmaceutical formulations and methods for use as inhibitors of matrix metallproteinase enzymes (MMPs).

  本发明涉及式（I）的化合物：其药学上可接受的盐，相应的制备过程，制药配方以及用作基质金属蛋白酶酶（MMPs）抑制剂的方法。
• Matrix Metalloproteinase Inhibitors
  申请人：Gaines Simon

  公开号：US20090082377A1

  公开（公告）日：2009-03-26

  The present invention relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, corresponding preparation processes, pharmaceutical formulations and methods for use as inhibitors of matrix metallproteinase enzymes (MMPs).

  本发明涉及公式（I）的化合物或其药学上可接受的盐，相应的制备方法，药物配方和用作基质金属蛋白酶酶（MMPs）抑制剂的方法。
• INHIBITORS OF MATRIX METALLOPROTEINASE
  申请人：GLAXO GROUP LIMITED

  公开号：EP1636174A1

  公开（公告）日：2006-03-22